Skip to main content
Botulinum Toxin A for the Treatment of Cervical Dystonia
Expert Opinion on Pharmacotherapy (2005)
  • Kelly L. Sullivan
  • Theresa A. Zesiewicz, University of South Florida
  • William Stamey, University of South Florida
  • Robert A. Hauser, University of South Florida
Idiopathic cervical dystonia (ICD) is the most common adult-onset focal dystonia. It is characterised by relatively sustained, involuntary contractions of neck muscles. Injections of botulinum toxin (BTX)-A are safe and effective for the treatment of ICD, and have substantially improved its treatment. BTX-A is manufactured by Allergan Pharmaceuticals in the US and Ireland, and is distributed as Botox®. In Europe, BTX-A is manufactured and distributed by Ipsen Pharmaceuticals as Dysport®. Success rates for BTX-A injections for ICD ranges 64 – 90%, with 76 – 93% of injected patients experiencing pain reduction. Side effects are generally mild and include dysphagia and neck weakness.
  • Cervical Dystonia,
  • Botulinum Toxin A,
  • Botox,
  • Dysport,
  • Treatment
Publication Date
February 25, 2005
Citation Information
Kelly L. Sullivan, Theresa A. Zesiewicz, William Stamey and Robert A. Hauser. "Botulinum Toxin A for the Treatment of Cervical Dystonia" Expert Opinion on Pharmacotherapy Vol. 5 Iss. 9 (2005) p. 2017 - 2024
Available at: